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Pancreatic islet transplantation in  
a simultaneous pancreas and kidney  
transplant recipient — a case report
ABSTRACT
Beta cell replacement allows for adequate blood glu-
cose control, reduced progression or even reversal of 
microvascular complications, and improves the quality 
of life. Simultaneous pancreas and kidney transplanta-
tion is the best therapeutic option for patients with 
type 1 diabetes and end-stage renal disease resulting 
from diabetic nephropathy. However, when pancreas 
transplantation is contraindicated or unavailable, pan-
creatic islet transplantation is an alternative minimally 
invasive procedure. We report a patient after earlier 
simultaneous kidney and pancreas transplantation 
with a failed pancreas graft, and no option for pan-
creas retransplantation. In this patient pancreatic islet 
transplantation was performed. The latter resulted 
in an improved blood glucose control, restoration of 
hypoglycaemia awareness, and improved quality of 
life with stable good function of the kidney allograft. 
(Clin Diabetol 2020; 9; 5: 338–343)
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Case report
We report a 41-year-old patient with type 1 diabetes 
since the age of 9, with chronic kidney disease (CKD) 
stage G5D due to diabetic nephropathy. At 32 years of 
age, half a year after entering a chronic haemodialysis 
programme, the patient underwent simultaneous kid-
ney and pancreas transplantation in the Department 
of General, Vascular, and Transplant Surgery, Medical 
University of Warsaw. At the time of kidney and pan-
creas transplantation, the patient was already blind 
due to diabetic retinopathy. No macroangiopathic 
complications were noted. Immediately after kidney 
and pancreas transplantation, the patient required 
reoperation for hematoma evacuation, followed by 
drainage of an infected fluid collection. Despite com-
plications, the patient did not require insulin support 
since the transplantation. At about 3 years after the 
transplantation, worsening followed by complete loss 
of the transplanted pancreas function was observed, 
with the need to reinitiate insulin, and a stable good 
function of the transplanted kidney with serum creati-
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nine levels of about 0.9 mg/dL. The patient remained 
under the care of the Transplantation Clinic at the 
Institute of Transplantology in Warsaw for 7 years, and 
then decided to transfer the care of the Transplantation 
Unit at the University Clinical Centre in Gdańsk.
At the time of care transition, blood glucose control 
was clearly unsatisfactory despite optimized therapy 
with multiple daily injections of insulin analogues 
glulisine and glargine, with haemoglobin A1c (HbA1c) 
levels of 7.7–8.7%. The daily insulin dose was about 
40–50 units. During continuous glucose monitoring 
(iPROTM2, Medtronic), the mean blood glucose level 
was 207 ± 76 mg/dL (Figure 1A). Blood glucose level 
was within the target range (70–180 mg/dL) for 42% 
of the time, and below the target range for 2% of the 
time. In addition, hypoglycaemia unawareness with 
the Gold score of 5 was an additional problem. The 
patient had large blood glucose level excursions with 
recurrent severe hypoglycaemia episodes during the last 
year. For this reason, the patient was offered pancreatic 
islet transplantation at Gdańsk Transplantation Center. 
The patient, who suffered from surgical complications 
following the initial pancreas transplantation, did not 
consent to another major surgery.
Despite a history of hepatitis C, neither viral replica-
tion nor evidence of hepatic damage were noted at the 
time of evaluation for pancreatic islet transplantation. 
Since simultaneous kidney and pancreas transplanta-
tion, the patient was receiving three immunosuppres-
sive drugs: prednisone, tacrolimus and mycophenolate 
sodium. His body weight was 56.5 kg, and his body 
mass index (BMI) was 20.8 kg/m2. Anti-HLA antibody 
testing was negative (Luminex Screen, Luminex Single 
Antigen). 
In addition to establishing the indications, the 
evaluation for pancreatic islet transplantation included 
the assessment of the severity of diabetes complica-
tions, technical feasibility of the procedure, exclusion 
of potential infection foci, screening for common ma-
lignancies and immunological evaluation. 
On October 27, 2018, the patient underwent trans-
plantation of 374,940 islet equivalents (IEQ), or 6,637 
IEQ per kg of body mass. The donor was a 26-year-old 
male who died due to craniocerebral trauma, with 
blood group 0 consistent with the blood group of 
the patient. Human leukocyte antigen (HLA) compat-
ibility included only one matching group A antigen 
(5 mismatches), but there were no repeated mis-
matches with the pancreas and kidney donor. The CDC 
and flow cytometry crossmatch testing was negative. 
Thymoglobulin and etanercept were used for induction. 
Overall, the patient received 6 mg/kg of Thymoglobulin 
and 125 mg of etanercept in fractionated doses over 
10 days. This is an off-label indication for etanercept. 
Tacrolimus and mycophenolate sodium were contin-
ued. The tacrolimus dose was transiently increased to 
achieve the serum trough level of 10–14 μg/L, myco-
phenolate sodium was increased to 720 mg twice daily, 
and prednisone was continued (5 mg/d). Pancreatic islet 
transplantation involved infusion of pancreatic islets 
in a special solution containing human albumin and 
heparin. The infusion was performed through a cath-
eter introduced percutaneously and transhepatically by 
an interventional radiologist to the main branch of the 
portal vein under ultrasonographic and fluoroscopic 
guidance. Following the procedure, a transient increase 
in transaminase activity, mild anaemia, and an increase 
in anti-GAD level from 21.86 IU/mL before transplanta-
tion to 1346.86 IU/ml (normal values < 10 IU/mL) at 14 
days after transplantation were observed, which was 
interpreted at this stage as an immunologic reaction 
to islet infusion and plasmapheresis was performed, 
resulting in a reduction of anti-GAD level to 283.18 IU/ 
/mL. Follow-up Doppler ultrasound of the portal system 
did not show evidence of thrombosis or the presence of 
a hematoma adjacent to the liver. The patient was given 
insulin to protect the pancreatic islets from excessive 
metabolic stimulation during islet engraftment into the 
hepatic tissue. Over several days, the daily insulin dose 
was gradually reduced to about 26 units (reduction 
by about 50%) and significantly lower blood glucose 
levels were observed. At 75 days after pancreatic islet 
transplantation, considered the end of the islet engraft-
ment period, a follow-up CGM (iPROTM2, Medtronic) 
was performed, showing a reduction in the variation 
of blood glucose levels, as evidenced by a reduction of 
the standard deviation of blood glucose levels from ± 
76 to ± 28 mg/dL. The proportion of time with blood 
glucose levels > 180 mg/dL was reduced from 56% to 
2%, and the proportion of time with low blood glucose 
levels (< 70 mg/dL) was reduced from 2% to 0% and 
no episode of severe hypoglycaemia was noted. The 
patient reported that the threshold of hypoglycaemia 
awareness increased to 50 mg/dL. The blood glucose 
level was within the target range (70–180 mg/dL) for 
98% of the time (Figure 1B). HbA1c level was 6.7%. 
Other laboratory testing at that time confirmed stable 
good function of the transplanted kidney, normal com-
plete blood count parameters, and absence of anti-HLA 
antibodies that would suggest humoral rejection.
During the next months after pancreatic islet 
transplantation, a gradual worsening of blood glucose 
control was observed, with an increase in HbA1c level to 
7.1%. During CGM (iPROTM2, Medtronic) at 9 months 
after islet transplantation, blood glucose level was 
within the target range (70–180 mg/dL) for 82% of the 
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time but the proportion of time with blood glucose 
level > 180 mg/dL increased from 2% to 13%. Also, 
the proportion of time with low blood glucose level 
(< 70 mg/dL) increased to 5% (Figure 1C).
A decision was made to repeat pancreatic islet 
transplantation from another donor. On September 
3, 2019, the patient underwent transplantation of 
366,134 IEQ, or 6,356 IEQ per kg of body mass. This 
time, the donor was a 20-year-old male who died due 
to a subarachnoid haemorrhage, with blood group 0 
consistent with the blood group of the patient. HLA 
compatibility included only one matching group A 
antigen (5 mismatches), but no repeated mismatches 
with the kidney and pancreas donor and the previous 
pancreatic islet donor were present. The CDC and flow 
cytometry crossmatch testing was negative. Basiliximab 
and etanercept were used for induction. The patient 
received the standard dose of basiliximab, two 20 mg 
doses, and 125 mg of etanercept in fractionated doses 
over 10 days. Tacrolimus, mycophenolate sodium and 
prednisone were continued.
Over several days, the daily insulin dose was 
gradually reduced to about 20 units (the dose was 
40–50 units per day before the first transplantation). 
At the end of the islet engraftment period at 75 days, 
when the daily insulin requirement was 12–14 units, 
another follow-up CGM (iPROTM2, Medtronic) record-
ing was performed. The standard deviation of blood 
glucose levels was ± 37 mg/dL. The proportion of time 
with blood glucose levels > 180 mg/dL was 10%, and 
the proportion of time with low blood glucose levels 
(< 70 mg/dL) was reduced to 1%. Blood glucose level 
was within the target range (70–180 mg/dL) for 89% 
of the time (Figure 1D). HbA1c level was 6.1%.
Currently, at 19 months since the initial pancreatic 
islet transplantation, the daily insulin requirement is 
12–13 units, and HbA1c level is 5.9% (Table 1). No epi-
sodes of severe hypoglycaemia have been noted. No 
significant complications have occurred since the initial 
pancreatic islet transplantation, either procedure-relat-
ed or resulting from the immunosuppressive therapy. 
The quality of life of both the patient and his family has 
improved significantly. The patient has become more 
active and has been involved in the community as a 
member of the local community board.
Discussion
Beta cell transplantation, either as the solid-organ 
pancreas or isolated pancreatic islets, is currently the 
only method to restore physiologic secretion of endog-
enous insulin. Pancreatic islet transplantation to the 
liver via the portal vein system is a safe minimally in-
vasive alternative to transplantation of the solid-organ 
pancreas [1]. Due to still suboptimal islet isolation tech-
niques, the efficacy of this process is limited and the 
number of islets yielded usually corresponds to 30–50% 
of islets in the whole pancreas. Thus, a single recipi-
ent typically requires two or three islet infusions from 
various donors to provide a satisfactory and relatively 
durable metabolic improvement. Achieving the state 
of insulin independence, although possible, particularly 
with repeated islet infusions from several donors, is not 
the major goal of pancreatic islet transplantation. The 
main goals include stabilization of the disease course, 
minimizing the risk of chronic complications, and 
a significant reduction or even elimination of the risk 
of life-threatening severe hypoglycaemia episodes.
For this reason, the indication for islet transplan-
tation as the minimally invasive alternative to solid-
organ pancreas transplantation is type 1 diabetes with 
recurrent severe hypoglycaemia episodes in patients 
with hypoglycaemia unawareness, i.e. unawareness 
of pathologically low blood glucose levels < 70 mg/dL 
without prodromal symptoms such as hunger and 
symptoms resulting from adrenergic (tremor, palpi-
tations, anxiety) and cholinergic system (sweating, 
paresthesiae) activation [2]. According to the 2018 
International Pancreas and Islets Transplant Association/ 
Table 1. Haemoglobin A1c (HbA1c) and peptide C levels and daily insulin doses at various time points
HbA1c  
level
Fasting peptide C 
level
Peptide C level following 
mixed meal stimulation
Daily insulin  
dose
Before kidney and pancreas transplantation No data 0 ng/ml – 64 units
1 year after kidney and pancreas transplantation No data No data No data 0 units 
3 years after kidney and pancreas transplantation No data No data 1.36 ng/mL 26 units 
8 years after kidney and pancreas transplantation 8.7% 0 ng/mL 0 ng/mL 40–50 units 
75 days after first pancreatic islet transplantation 6.7% 0.31 ng/mL 2.05 ng/mL 26 units 
9 months after first pancreatic islet transplantation 7.1% 0.38 ng/mL 1.52 ng/mL 26 units 
75 days after second pancreatic islet transplantation 6.1% 1.43 ng/mL 9.66 ng/mL 15 units 
9 months after second pancreatic islet transplantation 5.9% 1.42 ng/mL No data 12–13 units
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/European Pancreas and Islets Transplant Association 
(IPITA/EPITA) guidelines, indications for beta cell trans-
plantation in patients with type 1 diabetes include at 
least one documented severe hypoglycaemia episode 
in the last year, the proportion of low glucose levels 
(< 54 mg/dL) ≥ 5% during CGM, or hypoglycaemia 
unawareness with the Gold score of ≥ 5 along with 
evidence of poor blood glucose level control, such as 
Figure 1. Continuous glucose monitoring: A. before pancreatic islet transplantation; B. 75 days after pancreatic islet transplanta-
tion; C. 9 months after pancreatic islet transplantation; D. 75 days after the second pancreatic islet transplantation
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HbA1c level > 7.5–8.0%, and excessive blood glucose 
excursions, such as the CGM coefficient of variation ≥ 
30% or the standard deviation of blood glucose level 
during CGM ≥ 40 mg/dL [3]. In the reported patient, 
hypoglycaemia unawareness with the Gold score of ≥ 
5, HbA1c level of 8.3%, the standard deviation of blood 
glucose level during CGM of ± 76 mg/dL, and the CGM 
coefficient of variation of 37% were present.
It was shown that pancreatic islet transplantation was 
associated with an improvement in the quality of life only in 
those patients who reported hypoglycaemia unawareness 
and severe hypoglycaemia episodes requiring the help of 
other persons. In patients with blood glucose excursions 
that did not impair normal daily activities, no improvement 
in the quality of life was seen [4, 5]. Thus, the key to suc-
cessful patient selection for pancreatic islet transplantation, 
similarly to other procedures, are the realistic expectations 
of both the patient and the referring physician.
The patient selection process also includes the assess-
ment of procedure feasibility. This includes evidence of liver 
damage, synthetic function of the liver, presence of portal 
hypertension or hepatic lesions, such as arteriovenous 
anastomoses that might impair pancreatic islet infusion 
to the portal system or islet integration within the hepatic 
tissue. Currently available evidence indicates that the liver 
is the optimal site for pancreatic islet transplantation.
Transplantation of pancreatic islets from a deceased 
donor is associated with antigenic incompatibility, thus 
necessitating immunosuppressive therapy. For this rea-
son, the potential recipient must be evaluated for the 
presence of overt and latent infection foci and screened 
for the most common malignancies. Any abnormalities 
found constitute a contraindication only until the prob-
lem is resolved, e.g., a patient may receive pancreatic 
islets after oral cavity sanitation or after the infected 
ulcers of a diabetic foot are appropriately treated.
The standard immunosuppression regimen for 
pancreatic islet transplantation includes induction and 
maintenance therapy. Polyclonal antibodies resulting in 
lymphocyte depletion (thymoglobulin) or monoclonal 
antibodies against interleukin-2 receptor are most 
commonly used for the induction therapy. Due to an 
inflammatory reaction that accompanies islet infusion, 
this is combined with TNF-a blockade using etanercept 
[6, 7], an off-label indication for the latter drug.
If the patient already received a kidney or other organ 
transplant (e.g., heart, lung, liver) and is on chronic im-
munosuppressive therapy, the indications for pancreatic 
islet transplantation may be extended to patients with 
poor metabolic control only, without the history of severe 
hypoglycaemia, as the patient is only subjected to a mini-
mally invasive islet transfusion which is associated with a 
minimal risk of complications [7, 8]. The indications have 
been discussed in detail in a review paper that has been 
published in the same issue of the journal.
Liver bleeding may occur in 10% of patients, 
which usually requires a blood transfusion only, and 
only 1% of patients require surgical treatment. Portal 
vein thrombosis occurs rarely, in about 3% of patients, 
usually segmentally in small portal system branches, 
has no clinical significance and typically resolves with 
it anticoagulation without clinical sequelae.
In the reported case, pancreatic islet transplanta-
tion was performed due to failure of earlier pancreas 
transplantation and a high risk of severe hypoglycaemia 
despite optimized drug treatment with multiple insulin 
analogue injections. Following pancreas transplantation, 
the patient required reoperation due to surgical com-
plications. Although the kidney and the pancreas were 
transplanted simultaneously from the same donor, the 
pancreas transplant functioned for a significantly shorter 
time than the kidney transplant. The patient was insulin-
independent for only 3 years, and thereafter metabolic 
control was not satisfactory despite increasing insulin 
doses, with recurrent severe hypoglycaemia episodes. 
Pancreas transplantation is a major surgery with a sig-
nificant risk of severe surgical complications and treat-
ment failure. If it is successful, the patient may remain 
insulin-independent for many years. In the reported 
case, despite successful treatment of complication, the 
transplanted pancreas function had a limited duration. 
It is not clear what mechanism was responsible for the 
loss of the pancreas allograft function. As the function 
of the transplanted kidney was stable and good, alloag-
ression is unlikely as the underlying mechanism as both 
organs have the same histocompatibility antigens. Due 
to previous surgical complications and the need for re-
operation, the patient declined another pancreas trans-
plantation. It would have required at least two proce-
dures, i.e., removal of the non-functioning pancreas and 
another pancreas transplantation. It would have been 
technically difficult and associated with an increased 
complication risk due to previous operations, multiple 
adhesions, and the long time that had passed since the 
previous transplantation. Pancreatic islet infusion to the 
liver via the portal vein system was not associated with 
any complications. Despite two infusion procedures, 
the patient did not become insulin-independent but 
benefited from improved hypoglycaemia awareness and 
reduction of the risk of hypoglycaemia episodes which 
impaired his daily life activities. Metabolic control also 
improved significantly, as evidenced by lower HbA1c lev-
els and CGM parameters. Also of note, development of 
anti-HLA antibodies was not observed despite exposure 
to multiple incompatible HLA antigens with subsequent 
transplantations (kidney and pancreas transplantation 
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followed by two pancreatic islet infusions. The function 
of the transplanted kidney remained stable and good, 
with no development of proteinuria. It was possible 
with proper immunosuppressive therapy resulting in 
adequate immunosuppressive drug levels protecting 
from both cellular and humoral rejection. The patient has 
been receiving the same immunosuppressive drugs since 
the simultaneous pancreas and kidney transplantation. 
As noted, drug doses were transiently increased and 
are currently being gradually reduced with the intent of 
returning to the dosage regimen used before pancreatic 
islet transplantation.
Summary
Pancreatic islet transplantation is a safe, minimally 
invasive procedure that is not associated with any 
significant burden for the patient. This management 
approach seems to be optimal particularly in kidney 
transplant recipients who already receive immunosup-
pressive therapy to prevent kidney transplant rejection, 
as the added risk for the patient is very small in this 
clinical setting. Pancreatic islet transplantation follow-
ing kidney transplantation allows for stabilization of 
the clinical course of diabetes and minimization of the 
risk of life-threatening severe hypoglycaemia episodes.
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